Skip to main content
UniHealth

Doctor search

Theodore Leng, MD

Ophthalmology · Stanford

NPI 1144438987

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
25
6 carriers
Offices
8

Offices

8 locations · Stanford Health Care · University Healthcare Alliance · County of Santa Clara

Looking this up.

Hospitals listed: Santa Clara Valley Medical Center · Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

25 plans · 6 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Leng’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

25 of 25 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
Anthem Medicare Advantage (HMO-POS)Anthem Blue CrossListedOct 3, 2026
Blue Shield Inspire (HMO)Blue Shield of CaliforniaListedAug 26, 2026
Central Health Classic Care Plan III (HMO)Central Health Medicare PlanListedAug 15, 2026
Central Health Dual Access Plan (HMO D-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Embrace Care Plan (HMO C-SNP)Central Health Medicare PlanListed, may be out of dateSep 15, 2025
Central Health Embrace Choice Plan (HMO C-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Valor Care Plan (HMO)Central Health Medicare PlanListedAug 15, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A106892 · Current

Licensed to practise in California · since 2009 · expires 2027-03-31 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend it
    Overall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Santa Clara Valley Medical Center

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Santa Clara Valley Medical Center
SSI - Colon SurgeryInfections2.572WorseOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.563BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.256BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.369BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.25 (0.3 to 2.2) · 1,535 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.07 (0.76 to 1.38)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths214.59 (167.38 to 261.8) · 108 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.8 · 41 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6 · 141 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.2 · 124 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths8.3 · 501 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.9 · 653 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 348 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 4,502 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.24 (0.04 to 0.43) · 9,014 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.34 (0.15 to 0.52) · 9,216 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.54 (2.51 to 6.58) · 1,421 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.54 (0 to 3.2) · 288 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.11 (0.66 to 3.56) · 1,446 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths11.61 (4.09 to 19.14) · 294 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths7.29 (3.39 to 11.2) · 299 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.9 (0.45 to 3.36) · 333 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.23 (0 to 0.78) · 7,538 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths5.4 · 94 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.735No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections2.573No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.6 · 185 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits22.1 · 951 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits56.3 · 128 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits6.4 · 644 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits1.3 · 699 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.3 · 921 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (3.9 to 8.1) · 226 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.6 (9.4 to 16.5) · 226 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.4 · 94 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits11.4 · 54 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.3 · 242 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.2 (9.9 to 17.4) · 702 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.7 to 1.4) · 195 casesNo differentJan 2024 – Dec 2024

What patients said (4,032 patients answered, 29% of those asked)

Patient survey stars by topic at Santa Clara Valley Medical Center
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines3
Discharge information2
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Santa Clara Valley Medical Center
Room was "always" clean70%
Nurses "always" communicated well73%
Doctors "always" communicated well76%
Staff "always" explained57%
Yes, staff "did" give patients this information82%
Yes, staff "did" give patients information about help after discharge82%
Doctors "always" explained things so they could understand71%
Doctors "always" listened carefully74%
Doctors "always" treated them with courtesy and respect82%
Patients who gave a rating of "9" or "10" (high)67%
Staff "always" explained new medications71%
Nurses "always" explained things so they could understand71%
Nurses "always" listened carefully69%
Nurses "always" treated them with courtesy and respect80%
"Always" quiet at night43%
"YES", patients would definitely recommend the hospital70%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms83%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$316,891

Medicare paid this office $316,891 for 1,168 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)962$123,187$80
Injection of drug into eye201$104,920$92
Imaging of retina926$46,315$21
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's556$10,012$15
New patient visit (45+ min)72$6,207$86
See all 10 services
Every Original Medicare service billed
Return visit (30+ min)962$123,187$80
Injection of drug into eye201$104,920$92
Imaging of retina926$46,315$21
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's556$10,012$15
New patient visit (45+ min)72$6,207$86
Imaging of retina with remote review by physician78$1,003$13
Imaging of retina with remote review by physician43$595$14
Photography of the retina25$419$16
Measurement of corneal curvature and depth of eye14$367$24
Exam of visual field with extended testing14$299$21

Procedures Medicare counted

Procedure volume Medicare published
Cataract surgery11More than 32% of doctors who do this

Who their Medicare patients are

1,168 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 19% · Women 52% · Also on Medicaid 20% · Health risk score 1.37. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.

Conditions among them: High blood pressure 70% · Diabetes 46% · Coronary heart disease 26% · Chronic kidney disease 26% · Cancer 19% · Heart failure 15% · Atrial fibrillation 15% · Depression 14% · COPD 8% · Stroke 8% · Dementia 6%.

The office billed $2,583,038, Medicare allowed $432,359 and paid $316,891; for 5,898 services of 31 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20241,1685,898761.37$2,583,038$316,891
20231,0684,975771.47$2,019,972$303,686
20221,0684,772761.36$1,693,573$274,924
20211,0514,746761.40$1,696,589$292,954
20208624,129761.44$1,463,388$235,681
20199064,888751.50$1,824,365$295,908
20188604,823761.52$1,777,077$284,219
20178634,684761.53$1,930,354$285,357
20168554,897751.47$1,888,040$311,233
20158046,078761.48$3,376,658$1,006,747
20148276,059751.29$3,255,741$1,047,735
20137725,612751.43$2,864,397$826,816

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 10 services

Original Medicare services billed in 2023
Return visit (30+ min)874$115,041$83
Injection of drug into eye206$113,260$96
Imaging of retina870$47,004$23
New patient visit (45+ min)92$9,688$105
Imaging of retina with remote review by physician48$632$13
Short return visit (20+ min)11$571$48
Photography of the retina20$452$18
Imaging of retina with remote review by physician27$417$15
Measurement of corneal curvature and depth of eye13$400$29
Imaging of retina15$350$18

2022: 10 services

Original Medicare services billed in 2022
Injection of drug into eye194$102,139$88
Return visit (30+ min)826$98,002$78
Imaging of retina804$43,628$22
New patient visit (45+ min)79$8,307$105
Imaging of retina with remote review by physician61$880$14
Imaging of retina with remote review by physician55$859$16
Short return visit (20+ min)12$658$51
Photography of the retina23$431$17
Exam of visual field with extended testing14$353$24
Imaging of retina12$332$21

2021: 13 services

Original Medicare services billed in 2021
Injection of drug into eye188$104,855$92
Return visit (30+ min)735$89,726$84
Imaging of retina800$44,635$22
New patient visit (45+ min)99$11,384$115
Established patient complete exam of visual system131$4,352$33
Imaging of retina with remote review by physician70$1,251$17
Short return visit (20+ min)16$816$48
New patient complete exam of visual system12$814$68
Imaging of retina with remote review by physician33$575$17
Photography of the retina14$385$20
Measurement of corneal curvature and depth of eye14$297$21
Imaging of retina14$295$20
Imaging of retina with remote review by clinical staff12$80$7

2020: 14 services

Original Medicare services billed in 2020
Injection of drug into eye174$108,223$98
Return visit (30+ min)557$52,914$64
Imaging of retina632$37,930$22
New patient visit (45+ min)46$5,017$109
Short return visit (20+ min)77$2,905$36
Long return visit (40+ min)21$2,053$98
Injection of drug into eye18$1,646$82
Imaging of retina with remote review by clinical staff109$1,403$13
Return visit (30+ min)24$1,358$57
Imaging of retina38$820$21
Exam of retinal blood vessels using a special camera after injection of a dye15$632$40
New patient visit (30+ min)11$601$55
Measurement of corneal curvature and depth of eye11$303$28
Photography of the retina16$250$16

2019: 12 services

Original Medicare services billed in 2019
Injection of drug into eye192$122,699$99
Return visit (30+ min)642$69,910$66
Imaging of retina749$47,562$23
Removal of cataract with insertion of prosthetic lens11$9,955$622
New patient visit (45+ min)50$5,551$111
Long return visit (40+ min)53$5,140$95
Short return visit (20+ min)108$4,227$34
Established patient problem focused exam of visual system25$1,292$40
Injection of drug into eye11$950$63
Photography of the retina40$890$19
Imaging of retina23$666$21
Measurement of corneal curvature and depth of eye15$451$30

2018: 10 services

Original Medicare services billed in 2018
Injection of drug into eye187$121,058$97
Return visit (30+ min)601$66,573$64
Imaging of retina722$46,241$22
Short return visit (20+ min)151$7,368$40
New patient visit (45+ min)53$5,632$106
Long return visit (40+ min)21$1,989$95
Imaging of retina32$860$23
Return visit (30+ min)13$848$65
Short return visit (20+ min)13$597$43
Photography of the retina25$448$18

2017: 13 services

Original Medicare services billed in 2017
Injection of drug into eye188$111,113$97
Return visit (30+ min)612$66,694$63
Imaging of retina737$44,439$22
Removal of membrane of retina with removal of internal limiting membrane of retina14$16,148$1,077
Removal of cataract with insertion of prosthetic lens14$10,366$576
New patient visit (45+ min)73$6,870$94
Short return visit (20+ min)108$5,218$39
Long return visit (40+ min)50$4,780$96
Injection of drug into eye12$1,325$70
New patient visit (30+ min)14$902$64
Measurement of corneal curvature and depth of eye18$502$28
Photography of the retina26$427$16
Examination of eye by ophthalmoscope with retinal drawing11$201$18

2016: 17 services

Original Medicare services billed in 2016
Injection of drug into eye205$105,293$95
Imaging of retina739$50,092$25
Return visit (30+ min)353$37,606$63
Established patient complete exam of visual system414$35,296$67
Removal of membrane of retina with removal of internal limiting membrane of retina21$22,423$1,068
New patient visit (45+ min)122$12,787$105
Long return visit (40+ min)70$6,678$95
Exam of retinal blood vessels using a special camera after injection of a dye55$5,114$43
Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye33$4,323$58
Short return visit (20+ min)26$1,486$42
2d ultrasound scan of eye tissue and structures18$1,191$46
New patient visit (30+ min)12$662$55
Photography of the retina21$420$20
Exam of visual field with extended testing14$390$26
Measurement of corneal curvature and depth of eye12$349$29
Imaging of optic nerve12$271$21
Examination of eye by ophthalmoscope with retinal drawing14$256$18

2015: 19 services

Original Medicare services billed in 2015
Injection, aflibercept, 1 mg67$581,201None
Injection of drug into eye155$65,801$89
Injection of drug into eye102$54,987$110
Return visit (30+ min)438$47,708$65
Imaging of retina570$35,837$26
Imaging of retina176$26,979$45
Return visit (30+ min)158$23,489$90
Removal of membrane of retina with removal of internal limiting membrane of retina19$19,438$1,023
New patient visit (45+ min)100$10,702$107
Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye28$10,319$265
Exam of retinal blood vessels using a special camera after injection of a dye76$7,023$43
Exam of retinal blood vessels using a special camera after injection of a dye44$6,951$105
Unclassified biologics34$6,623None
Exam of blood vessels between the white part of eye and retina using a special camera after injection of a dye44$5,696$59
Established patient complete exam of visual system84$5,677$62
2d ultrasound scan of eye tissue and structures22$1,193$50
Short return visit (20+ min)13$990$71
Short return visit (20+ min)18$955$45
Photography of the retina32$691$21

2014: 23 services

Original Medicare services billed in 2014
Injection, aflibercept, 1 mg54$590,398None
Injection, ranibizumab, 0.1 mg16$114,544None
Injection of drug into eye90$64,602$106
Injection of drug into eye124$56,966$89
Return visit (30+ min)384$38,405$64
Imaging of retina564$32,054$25
Imaging of retina176$30,877$43
Return visit (30+ min)144$20,486$89
Removal of membrane of retina with removal of internal limiting membrane of retina12$18,623$1,433
Unclassified biologics36$9,430None
New patient visit (45+ min)82$8,249$101
Established patient complete exam of visual system104$7,007$64
Exam of retinal blood vessels using a special camera after injection of a dye38$3,629$44
Exam of retinal blood vessels using a special camera after injection of a dye26$3,038$108
Established patient complete exam of visual system14$1,565$98
New patient complete exam of visual system22$1,322$60
2d ultrasound scan of eye tissue and structures13$965$48
Short return visit (20+ min)20$925$44
Photography of the retina28$710$20
Examination of eye by ophthalmoscope with retinal drawing30$587$20
Examination of eye by ophthalmoscope with retinal drawing23$517$17
Examination of eye by ophthalmoscope with retinal drawing20$497$24
Examination of eye by ophthalmoscope with retinal drawing11$268$24

2013: 25 services

Original Medicare services billed in 2013
Injection, aflibercept, 1 mg37$350,137None
Injection, ranibizumab, 0.1 mg13$104,736None
Injection of drug into eye139$51,196$88
Return visit (30+ min)370$46,776$64
Injection of drug into eye70$40,542$99
Removal of membrane of retina with removal of internal limiting membrane of retina28$39,444$1,409
Imaging of retina515$29,172$25
Return visit (30+ min)120$26,771$90
Imaging of retina145$22,015$43
Complex repair of detached retina and drainage of eye fluid between lens and retina13$20,859$1,605
New patient visit (45+ min)93$9,748$105
Short return visit (20+ min)140$7,700$42
Unclassified biologics27$5,293None
Short return visit (20+ min)50$4,883$64
Exam of retinal blood vessels using a special camera after injection of a dye31$4,420$110
Exam of retinal blood vessels using a special camera after injection of a dye54$4,228$40
Examination of eye by ophthalmoscope with retinal drawing52$2,152$23
Examination of eye by ophthalmoscope with retinal drawing73$2,064$17
2d ultrasound scan of eye tissue and structures22$1,668$45
New patient visit (45+ min)11$1,547$141
Long return visit (40+ min)11$1,453$132
New patient complete exam of visual system14$957$68
Examination of eye by ophthalmoscope with retinal drawing42$749$18
Photography of the retina16$385$20
Examination of eye by ophthalmoscope with retinal drawing16$385$24

Medicaid work

$105,159 in 2024

Medicaid paid $105,159 for 1,793 billed services this clinician did in 2024, up to 69 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Intravitreal injection of a pharmacologic agent (separate procedure)616$59,473
Aflibercept injection46$25,609
Return visit (30+ min)349$13,176
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina746$6,787
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)36$114
Medicaid work by year
20241,793569$105,159
20232,015475$118,599
20221,272457$46,308
20211,112559$51,569
20201,172357$48,476
20191,715462$106,153
20181,772464$176,299
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Intravitreal injection of a pharmacologic agent (separate procedure)700$64,834
Aflibercept injection67$36,403
Return visit (30+ min)433$9,746
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina815$7,616

2022

Largest Medicaid services in 2022
Intravitreal injection of a pharmacologic agent (separate procedure)382$32,883
Return visit (30+ min)326$7,696
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina551$5,729
Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr)13$0

2021

Largest Medicaid services in 2021
Intravitreal injection of a pharmacologic agent (separate procedure)287$38,625
Return visit (30+ min)260$6,468
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina524$5,572
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST29$904
Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr)12$0

2020

Largest Medicaid services in 2020
Intravitreal injection of a pharmacologic agent (separate procedure)469$39,766
Return visit (30+ min)235$4,782
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina468$3,927

2019

Largest Medicaid services in 2019
Intravitreal injection of a pharmacologic agent (separate procedure)622$61,132
Aflibercept injection36$30,508
Return visit (30+ min)330$7,332
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina727$7,181

2018

Largest Medicaid services in 2018
Aflibercept injection140$89,633
Intravitreal injection of a pharmacologic agent (separate procedure)624$70,957
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina671$8,161
Return visit (30+ min)337$7,548

Drugs they prescribed that Part D paid

$8,514

Pharmacies billed $8,514 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 155) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.

113 generic and 42 brand-name prescriptions · $8,514 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Azelastine22$1,829$34
Prednisolone Acetate13$756$31
Ketorolac Tromethamine11$476$20

Year by year

Part D prescribing by year
2024155550% (0)27%$8,514
2023167580% (0)28%$14,966
2022222720% (0)18%$26,091
2021221770% (0)30%$26,209
2020166610% (0)51%$27,325
2019122530% (0)50%$12,846
2018111360% (0)51%$11,100
2017155520% (0)58%$156,630
2016144540% (0)53%$14,945
201511750None79%$11,766
201494420% (0)82%$11,250
2013132600% (0)68%$10,799

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 5 drugs

Part D drugs prescribed in 2023
Azelastine49$2,093$43
Bromfenac16$1,354$85
Prednisolone Acetate22$967$44
Ketorolac Tromethamine13$413$32
Erythromycin15$201$13

2022: 6 drugs

Part D drugs prescribed in 2022
Xiidra15$10,077$672
Azelastine94$3,828$41
Valganciclovir13$2,717$209
Prednisolone Acetate15$894$60
Olopatadine12$584$49
Ketorolac Tromethamine28$473$17

2021: 5 drugs

Part D drugs prescribed in 2021
Restasis16$12,884$805
Azelastine74$2,902$39
Ketorolac Tromethamine49$1,631$33
Prednisolone Acetate31$1,615$52
Olopatadine13$1,486$114

2020: 5 drugs

Part D drugs prescribed in 2020
Restasis21$17,505$834
Prednisolone Acetate44$2,281$52
Ketorolac Tromethamine32$1,023$32
Azelastine18$735$41
Latanoprost12$161$13

2019: 3 drugs

Part D drugs prescribed in 2019
Prednisolone Acetate43$2,000$47
Azelastine14$546$39
Ketorolac Tromethamine18$458$25

2018: 3 drugs

Part D drugs prescribed in 2018
Prednisolone Acetate32$1,417$44
Azelastine15$637$42
Timolol Maleate11$126$11

2017: 3 drugs

Part D drugs prescribed in 2017
Prednisolone Acetate43$2,530$59
Azelastine34$1,531$45
Latanoprost21$189$9

2016: 3 drugs

Part D drugs prescribed in 2016
Prednisolone Acetate41$3,404$83
Olopatadine20$1,918$96
Latanoprost14$175$12

2015: 3 drugs

Part D drugs prescribed in 2015
Prednisolone Acetate54$4,759$88
Patanol12$2,879$240
Eplerenone12$515$43

2014: 2 drugs

Part D drugs prescribed in 2014
Prednisolone Acetate36$3,121$87
Nevanac12$2,090$174

2013: 2 drugs

Part D drugs prescribed in 2013
Nevanac17$2,537$149
Prednisolone Acetate50$1,419$28

Money from drug and device companies

$42,884 in 2025

Industry payments by year
20251435$40,981$42,884
20241034$39,047$51,687
20231233$27,524$29,603
20221144$37,926$42,882
2021816$35,650$36,067
202048$16,755$16,774
201989$2,128$2,684

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Topcon HealthcareNone$24,529
15 payments
  • Consulting · 2025-12-08 · $2,000
  • Consulting · 2025-11-10 · $2,000
  • Consulting · 2025-10-14 · $2,000
  • Consulting · 2025-09-15 · $2,000
  • Consulting · 2025-08-18 · $2,000
  • Travel · 2025-07-21 · $315
  • Travel · 2025-07-21 · $178
  • Travel · 2025-07-21 · $35
  • Consulting · 2025-07-07 · $2,000
  • Consulting · 2025-06-09 · $2,000
  • Consulting · 2025-05-12 · $2,000
  • Consulting · 2025-04-14 · $2,000
  • Consulting · 2025-03-10 · $2,000
  • Consulting · 2025-02-10 · $2,000
  • Consulting · 2025-01-13 · $2,000
Boehringer Ingelheim PharmaceuticalsNone$5,700
1 payment
  • Consulting · 2025-06-23 · $5,700
GenentechCellcept$4,200
1 payment
  • Consulting for Cellcept · 2025-05-08 · $4,200
Apellis PharmaceuticalsSyfovre$2,871
2 payments
  • Consulting for Syfovre · 2025-10-10 · $2,816
  • Meals · 2025-09-12 · $55
Boehringer Ingelheim International GmbHNone$2,325
3 payments
  • Consulting · 2025-04-07 · $850
  • Consulting · 2025-01-13 · $1,275
  • Travel · 2025-01-13 · $200
Digital DiagnosticsLumineticscore$1,200
1 payment
  • Consulting for Lumineticscore · 2025-03-02 · $1,200
See all 34 published payments
Every published payment
Topcon HealthcareConsulting · 2025-12-08None$2,000
Regeneron PharmaceuticalsMeals · 2025-12-04Eylea Hd$75
Topcon HealthcareConsulting · 2025-11-10None$2,000
Astellas Pharma USMeals · 2025-10-16Izervay$129
Topcon HealthcareConsulting · 2025-10-14None$2,000
Apellis PharmaceuticalsConsulting · 2025-10-10Syfovre$2,816
Topcon HealthcareConsulting · 2025-09-15None$2,000
Apellis PharmaceuticalsMeals · 2025-09-12None$55
Astellas Pharma USMeals · 2025-09-11Izervay$42
Ocular TherapeutixMeals · 2025-09-11Dextenza$214
Beaver-Visitec InternationalMeals · 2025-09-04None$17
Topcon HealthcareConsulting · 2025-08-18None$2,000
Alcon VisionMeals · 2025-08-02Constellation$133
Topcon HealthcareTravel · 2025-07-21None$315
Topcon HealthcareTravel · 2025-07-21None$178
Topcon HealthcareTravel · 2025-07-21None$35
Topcon HealthcareConsulting · 2025-07-07None$2,000
Regeneron Healthcare SolutionsConsulting · 2025-06-27Eylea Hd$940
Boehringer Ingelheim PharmaceuticalsConsulting · 2025-06-23None$5,700
Astellas Pharma Global DevelopmentMeals · 2025-06-17Izervay$160
Topcon HealthcareConsulting · 2025-06-09None$2,000
Astellas Pharma Global DevelopmentMeals · 2025-06-05Izervay$158
Topcon HealthcareConsulting · 2025-05-12None$2,000
GenentechConsulting · 2025-05-08Cellcept$4,200
Alcon VisionMeals · 2025-04-14Constellation$150
Topcon HealthcareConsulting · 2025-04-14None$2,000
Boehringer Ingelheim International GmbHConsulting · 2025-04-07None$850
Topcon HealthcareConsulting · 2025-03-10None$2,000
Digital DiagnosticsConsulting · 2025-03-02Lumineticscore$1,200
Topcon HealthcareConsulting · 2025-02-10None$2,000
Genentech USAMeals · 2025-02-07Vabysmo$42
Boehringer Ingelheim International GmbHConsulting · 2025-01-13None$1,275
Boehringer Ingelheim International GmbHTravel · 2025-01-13None$200
Topcon HealthcareConsulting · 2025-01-13None$2,000
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $51,687

Payments by company in 2024
Boehringer Ingelheim International GmbHNone$20,648
9 payments
  • Paid to speak or teach · 2024-12-09 · $800
  • Travel · 2024-12-09 · $11,452
  • Consulting · 2024-11-11 · $2,975
  • Paid to speak or teach · 2024-07-12 · $233
  • Paid to speak or teach · 2024-07-10 · $513
  • Consulting · 2024-05-17 · $425
  • Consulting · 2024-03-04 · $638
  • Consulting · 2024-02-12 · $1,063
  • Consulting · 2024-01-09 · $2,550
Topcon HealthcareNone$15,000
4 payments
  • Consulting · 2024-12-09 · $2,000
  • Consulting · 2024-11-02 · $2,000
  • Consulting · 2024-10-15 · $8,000
  • Consulting · 2024-06-18 · $3,000
F. Hoffmann-La Roche AGNone$6,352
4 payments
  • Consulting · 2024-09-18 · $2,748
  • Meals · 2024-07-18 · $17
  • Consulting · 2024-07-18 · $840
  • Consulting · 2024-05-13 · $2,748
Regeneron Healthcare SolutionsEylea Hd$4,860
2 payments
  • Consulting for Eylea Hd · 2024-02-23 · $1,620
  • Consulting for Eylea Hd · 2024-02-23 · $3,240
GenentechNone$3,656
2 payments
  • Consulting · 2024-04-25 · $3,150
  • Consulting · 2024-01-26 · $506
Genentech USAVabysmo$543
5 payments
  • Meals · 2024-10-17 · $204
  • Meals for Vabysmo · 2024-09-13 · $116
  • Meals for Susvimo · 2024-07-17 · $100
  • Meals for Vabysmo · 2024-03-20 · $23
  • Meals for Vabysmo · 2024-02-09 · $100
Astellas Pharma USIzervay$287
2 payments
  • Meals for Izervay · 2024-04-22 · $150
  • Meals for Izervay · 2024-03-05 · $137
Regeneron PharmaceuticalsEylea$249
4 payments
  • Meals for Eylea · 2024-09-11 · $86
  • Meals for Eylea · 2024-07-19 · $94
  • Meals for Eylea Hd · 2024-05-09 · $26
  • Meals for Eylea Hd · 2024-02-09 · $42
Astellas Pharma Global DevelopmentIzervay$55
1 payment
  • Meals for Izervay · 2024-05-06 · $55
Boehringer Ingelheim PharmaceuticalsNone$37
1 payment
  • Meals · 2024-09-13 · $37

2023: $29,603

Payments by company in 2023
Alcon VisionConstellation$15,814
14 payments
  • Travel for Constellation · 2023-10-19 · $66
  • Travel for Constellation · 2023-10-19 · $72
  • Consulting for Constellation · 2023-10-19 · $12,250
  • Meals for Constellation · 2023-10-19 · $9
  • Meals for Constellation · 2023-10-19 · $43
  • Travel for Constellation · 2023-10-06 · $160
  • Travel for Constellation · 2023-10-06 · $221
  • Travel · 2023-10-06 · $249
  • Travel · 2023-10-06 · $263
  • Meals · 2023-10-06 · $171
  • Travel · 2023-08-10 · $13
  • Travel · 2023-08-10 · $17
  • Consulting · 2023-08-10 · $2,100
  • Meals · 2023-07-30 · $181
Boehringer Ingelheim International GmbHNone$5,950
3 payments
  • Consulting · 2023-11-07 · $2,550
  • Consulting · 2023-06-02 · $850
  • Consulting · 2023-05-02 · $2,550
F. Hoffmann-La Roche AGNone$2,944
1 payment
  • Consulting · 2023-03-01 · $2,944
Alcon ResearchNone$2,100
3 payments
  • Consulting · 2023-11-09 · $700
  • Consulting · 2023-08-10 · $700
  • Consulting · 2023-06-08 · $700
GenentechNone$1,680
3 payments
  • Consulting · 2023-12-26 · $675
  • Consulting · 2023-08-28 · $675
  • Consulting · 2023-02-27 · $330
IridexNone$500
1 payment
  • Honoraria · 2023-11-18 · $500
Astellas Pharma USNone$184
2 payments
  • Meals · 2023-08-02 · $35
  • Meals · 2023-08-02 · $149
Regeneron Healthcare SolutionsEylea Hd$144
1 payment
  • Meals for Eylea Hd · 2023-10-31 · $144
BiogenNone$128
1 payment
  • Meals · 2023-01-25 · $128
Genentech USAVabysmo$59
2 payments
  • Meals for Vabysmo · 2023-08-16 · $38
  • Meals for Vabysmo · 2023-03-22 · $21
Regeneron PharmaceuticalsEylea$51
1 payment
  • Meals for Eylea · 2023-04-25 · $51
Ocular TherapeutixDextenza$50
1 payment
  • Meals for Dextenza · 2023-07-30 · $50

2022: $42,882

Payments by company in 2022
Alcon VisionLuxor$12,727
11 payments
  • Meals for Luxor · 2022-11-14 · $59
  • Consulting for Ngenuity · 2022-11-14 · $2,100
  • Consulting for Luxor · 2022-11-14 · $9,100
  • Travel for Ngenuity · 2022-11-14 · $16
  • Travel for Luxor · 2022-11-14 · $47
  • Travel · 2022-10-28 · $455
  • Meals · 2022-10-28 · $256
  • Meals · 2022-10-28 · $58
  • Travel · 2022-10-28 · $161
  • Travel · 2022-10-28 · $454
  • Meals for Constellation · 2022-01-31 · $21
F. Hoffmann-La Roche AGNone$11,775
4 payments
  • Consulting · 2022-10-01 · $1,178
  • Consulting · 2022-07-01 · $3,140
  • Consulting · 2022-05-13 · $4,710
  • Consulting · 2022-03-29 · $2,748
Apellis PharmaceuticalsNone$4,853
9 payments
  • Travel · 2022-12-02 · $1,562
  • Consulting · 2022-11-14 · $2,816
  • Meals · 2022-10-01 · $88
  • Meals · 2022-10-01 · $50
  • Meals · 2022-09-14 · $128
  • Meals · 2022-07-16 · $54
  • Meals · 2022-07-15 · $64
  • Meals · 2022-05-02 · $19
  • Meals · 2022-05-01 · $72
GenentechVabysmo$4,575
5 payments
  • Consulting · 2022-12-27 · $660
  • Consulting · 2022-12-01 · $660
  • Consulting · 2022-09-15 · $495
  • Meals for Vabysmo · 2022-03-22 · $120
  • Consulting · 2022-02-25 · $2,640
Genentech USAVabysmo$3,568
4 payments
  • Meals for Vabysmo · 2022-09-29 · $176
  • Travel for Vabysmo · 2022-09-28 · $114
  • Travel for Vabysmo · 2022-09-28 · $458
  • Consulting for Vabysmo · 2022-09-28 · $2,820
Regeneron Healthcare SolutionsEylea$3,272
5 payments
  • Meals for Eylea · 2022-10-25 · $7
  • Consulting for Eylea · 2022-08-26 · $1,080
  • Consulting for Eylea · 2022-06-10 · $1,080
  • Consulting for Eylea · 2022-03-25 · $1,080
  • Meals for Eylea · 2022-03-03 · $25
EyePoint Pharmaceuticals USYutiq$1,620
1 payment
  • Consulting for Yutiq · 2022-08-09 · $1,620
Dompe USOxervate$153
1 payment
  • Meals for Oxervate · 2022-11-08 · $153
Johnson & Johnson Surgical VisionTecnis Iol$119
1 payment
  • Meals for Tecnis Iol · 2022-05-17 · $119
Alimera SciencesIluvien$114
1 payment
  • Meals for Iluvien · 2022-02-15 · $114
Regeneron PharmaceuticalsEylea$106
2 payments
  • Meals for Eylea · 2022-10-01 · $41
  • Meals for Eylea · 2022-08-09 · $65

2021: $36,067

Payments by company in 2021
GenentechNone$12,450
6 payments
  • Consulting · 2021-12-07 · $2,310
  • Consulting · 2021-10-19 · $1,650
  • Consulting · 2021-10-05 · $990
  • Consulting · 2021-09-03 · $1,890
  • Consulting · 2021-03-02 · $495
  • Consulting · 2021-01-06 · $5,115
Regeneron Healthcare SolutionsEylea$10,832
3 payments
  • Meals for Eylea · 2021-09-30 · $32
  • Consulting for Eylea · 2021-06-25 · $5,400
  • Consulting for Eylea · 2021-02-12 · $5,400
Boehringer Ingelheim International GmbHNone$6,800
1 payment
  • Consulting · 2021-03-02 · $6,800
Alcon VisionConstellation$4,900
1 payment
  • Consulting for Constellation · 2021-06-04 · $4,900
Alcon ResearchLuxor$700
1 payment
  • Consulting for Luxor · 2021-10-22 · $700
Genentech USASusvimo$190
2 payments
  • Meals for Susvimo · 2021-11-13 · $149
  • Meals for Lucentis · 2021-06-11 · $41
Alimera SciencesIluvien$119
1 payment
  • Meals for Iluvien · 2021-06-21 · $119
Apellis PharmaceuticalsNone$76
1 payment
  • Meals · 2021-11-15 · $76

2020: $16,774

Payments by company in 2020
GenentechNon-Covered Product$7,275
4 payments
  • Consulting · 2020-12-04 · $3,465
  • Consulting · 2020-11-03 · $1,320
  • Consulting · 2020-10-29 · $990
  • Consulting for Non-Covered Product · 2020-02-07 · $1,500
Regeneron Healthcare SolutionsEylea$6,480
2 payments
  • Consulting for Eylea · 2020-12-17 · $5,400
  • Consulting for Eylea · 2020-08-13 · $1,080
Carl Zeiss MeditecCirrus Hd-Oct$3,000
1 payment
  • Consulting for Cirrus Hd-Oct · 2020-01-03 · $3,000
Carl Zeiss Meditec AGNone Specified$19
1 payment
  • Gift for None Specified · 2020-05-08 · $19

2019: $2,684

Payments by company in 2019
F. Hoffmann-La Roche AGLucentis$2,128
1 payment
  • Paid to speak or teach for Lucentis · 2019-03-31 · $2,128
Alcon VisionConstellation$132
1 payment
  • Meals for Constellation · 2019-11-04 · $132
Alimera SciencesIluvien$125
1 payment
  • Meals for Iluvien · 2019-09-23 · $125
GenentechLucentis$102
1 payment
  • Meals for Lucentis · 2019-06-10 · $102
EyePoint Pharmaceuticals USYutiq$93
2 payments
  • Meals for Yutiq · 2019-10-12 · $71
  • Meals for Yutiq · 2019-03-23 · $22
Carl Zeiss MeditecNone$70
1 payment
  • Meals · 2019-05-31 · $70
Regeneron Healthcare SolutionsEylea$20
1 payment
  • Meals for Eylea · 2019-02-24 · $20
Genentech USALucentis$15
1 payment
  • Meals for Lucentis · 2019-12-03 · $15

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Astellas Pharma Global Development · A Staged Study Incorporating A Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and A Phase 2, Multicenter, Unmasked, Randomized, Parallel-Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of Asp7317 for Atrophy Secondary To Age-Related Macular Degeneration · 2023Their institution$22,197
Astellas Pharma Global Development · A Staged Study Incorporating A Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and A Phase 2, Multicenter, Unmasked, Randomized, Parallel-Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of Asp7317 for Atrophy Secondary To Age-Related Macular Degeneration · 2022Their institution$19,590
TOPCON CORPORATION · Triton Oct-A Pre-Study Pilot 2 · 2020Their institution$18,075
TOPCON CORPORATION · Trition Oct-A Pre-Study Pilot 1 · 2019Their institution$10,498
Genentech, Inc. · Va2 Phiii Yosemite · 2019Their institution$10,177
Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2025This clinician$10,172
F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: the Faretina-Dme Study · 2024This clinician$6,028
F. Hoffmann-La Roche AG · Comparison of the Relative Effectiveness of Faricimab Vs Aflibercept 8 Mg in Diabetic Macular Edema (Dme) · 2024This clinician$4,448
F. Hoffmann-La Roche AG · Iris: the Intelligent Retinal Imaging System · 2023This clinician$4,352
F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab: the Faretina-Amd Study · 2024This clinician$4,216
F. Hoffmann-La Roche AG · Long-Term Experience With Intravitreal Anti-Vegf in Patients With Namd Analysis of Intelligent Research in Sight Iris Registry Database · 2021This clinician$3,930
Genentech, Inc. · Va2 Phiii Yosemite · 2020Their institution$3,584
F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration (Namd) Treated With Faricimab: the Faretina-Amd Study · 2024This clinician$3,347
F. Hoffmann-La Roche AG · How Intravitreal Anti-Vascular Endothelial Growth Factor Initial Dosing Impacts Patient Outcomes in Diabetic Macular Edema · 2024This clinician$3,135
F. Hoffmann-La Roche AG · How Intravitreal Anti-Vascular Endothelial Growth Factor Loading Doses Impact Patient Outcomes in Diabetic Macular Edema · 2023This clinician$2,805
F. Hoffmann-La Roche AG · Early Treatment Patterns and Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: the Faretina-Dme Study · 2023This clinician$2,104
F. Hoffmann-La Roche AG · Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: the Faretina-Amd Study · 2023This clinician$2,104
F. Hoffmann-La Roche AG · Two-Year Real-World Clinical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab in the US: the Faretina-Dme Study · 2025This clinician$1,864
F. Hoffmann-La Roche AG · Comparative Efficacy of Faricimab for the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis · 2024This clinician$1,566
F. Hoffmann-La Roche AG · 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Neovascular Age-Related Macular Degeneration: Faretina-Amd · 2025This clinician$1,556
F. Hoffmann-La Roche AG · 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema: the Faretina-Dme Study · 2025This clinician$1,556
F. Hoffmann-La Roche AG · Real-World Effectiveness of Faricimab in Patients With Diabetic Macular Edema: 12-Month Outcomes From Faretina-Dme and Farwide-Dme Studies · 2024This clinician$1,417
F. Hoffmann-La Roche AG · Real-World Effectiveness of Faricimab in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Outcomes From Faretina-Namd and Farwide-Namd Studies · 2024This clinician$1,417
F. Hoffmann-La Roche AG · 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Neovascular Age-Related Macular Degeneration: Faretina-Amd · 2024This clinician$1,416
F. Hoffmann-La Roche AG · Real-World Clinical Outcomes Update in Patients With Diabetic Macular Edema Treated With Faricimab in the US: the Faretina-Dme Study · 2025This clinician$1,370
F. Hoffmann-La Roche AG · Real-World Clinical Outcomes Update in Patients With Neovascular Age-Related Macular Degeneration in the US: the Faretina-Amd Study · 2025This clinician$1,370
Astellas Pharma Global Development · A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of Asp7317 for Geographic Atrophy Secondary To Age-Related Macular Degeneration · 2022Their institution$1,244
F. Hoffmann-La Roche AG · 2-Year Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration (Namd) and Diabetic Macular Edema (Dme) Treated With Faricimab in the United States: the Faretina Study · 2025This clinician$1,206
F. Hoffmann-La Roche AG · Two-Year Real-World Clinical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab in the US: the Faretina-Namd Study · 2025This clinician$1,200
F. Hoffmann-La Roche AG · 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema: the Faretina-Dme Study · 2024This clinician$1,117
F. Hoffmann-La Roche AG · Uk Faricimab Real-World Evidence (Uk Farwide) Study: Evaluation of Faricimab Uptake Patient Characteristics Treatment Patterns and Visual Acuity Outcomes Over Time · 2024This clinician$1,113
F. Hoffmann-La Roche AG · Early Treatment Patterns and Outcomes in Diabetic Macular Edema Patients Initiating Faricimab in the US and Uk · 2023This clinician$1,096
F. Hoffmann-La Roche AG · Faretina-Dme-Six-Month Treatment Patterns and Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: An Iris (Tm) Registry Analysis · 2023This clinician$1,096
F. Hoffmann-La Roche AG · Early Treatment Patterns and Outcomes in Neovascular Age-Related Macular Degeneration (Namd) Patients Initiating Faricimab in the US and Uk · 2023This clinician$1,096
F. Hoffmann-La Roche AG · Iris Namd Treatment Patterns Study · 2021This clinician$509
F. Hoffmann-La Roche AG · Comparative Efficacy of Faricimab for the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis · 2023This clinician$481
F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: the Faretina-Dme Study · 2023This clinician$480
F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab: the Faretina-Amd Study · 2023This clinician$480
F. Hoffmann-La Roche AG · Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema (Dme) and Neovascular Age-Related Macular Degeneration (Namd) Treated With Faricimab in the United States: the Faretina Study · 2024This clinician$426
F. Hoffmann-La Roche AG · Two-Year Real-World Clinical Outcomes Update With Faricimab in Patients With Neovascular Age-Related Macular Degeneration in the USA: the Faretina-Amd Study · 2024This clinician$421
F. Hoffmann-La Roche AG · 12-Month Real-World Clinical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab in the USA: the Faretina-Dme Study · 2024This clinician$421
F. Hoffmann-La Roche AG · Faretina-Dme Real-World Injection Frequency, Visual Acuity and Anatomical Outcomes ?12-Month Follow Up · 2023This clinician$359
F. Hoffmann-La Roche AG · Indirect Comparison of the Relative Effectiveness of Faricimab Vs Aflibercept 8 Mg in Dme and Namd · 2025This clinician$306
F. Hoffmann-La Roche AG · 2-Year Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration (Namd) and Diabetic Macular Edema (Dme) Treated With Faricimab in the United States: the Faretina Study · 2024This clinician$296

Professional record

NPI
1144438987
Licence
CA A106892California A106892: Current · expires 2027-03-31
Trained
Stanford University School of Medicine, 2005
Group
Stanford Health Care · University Healthcare Alliance · County of Santa Clara
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
Mailing address
2452 Watson Ct, Palo Alto, CA, 94303
NPI first listed
2007-05-17
NPI last updated
2024-03-21
NPI record certified
2024-03-21

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 2452 Watson Ct, Palo Alto, CA, 94303